hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of P140K MGMT hematopoietic stem cells,
O6-benzylguanine, temozolomide, and carmustine in treating participants with supratentorial
glioblastoma or gliosarcoma who have recently had surgery to remove most or all of the brain
tumor (resected). Chemotherapy drugs, such as 6-benzylguanine, temozolomide, and carmustine,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing. Placing P140K MGMT, a gene that has been created in the
laboratory into bone marrow making the bone more resistant to chemotherapy, allowing
intra-patient dose escalation which kills more tumor cells while allowing bone marrow to
survive.